Polyethylenimine-grafted polyamidoamine conjugates for gene delivery with high efficiency and low cytotoxicity

2014 ◽  
Vol 22 (7) ◽  
pp. 757-764 ◽  
Author(s):  
Tae-Hun Kim ◽  
Ho Won Seo ◽  
Jin Han ◽  
Kyung Soo Ko ◽  
Joon Sig Choi
2006 ◽  
Vol 38 (11) ◽  
pp. 780-787 ◽  
Author(s):  
Wei DONG ◽  
Guang-Hui JIN ◽  
Shu-Feng LI ◽  
Qi-Ming SUN ◽  
Ding-Yuan MA ◽  
...  

2012 ◽  
Vol 23 (1-4) ◽  
pp. 315-331 ◽  
Author(s):  
Wen He ◽  
Zhenhuan Guo ◽  
Yuting Wen ◽  
Qian Wang ◽  
Bimei Xie ◽  
...  

2020 ◽  
Vol 8 (12) ◽  
pp. 2418-2430 ◽  
Author(s):  
Jing Zhao ◽  
Ihsan Ullah ◽  
Bin Gao ◽  
Jintang Guo ◽  
Xiang-kui Ren ◽  
...  

Agmatine-grafted bioreducible poly(l-lysine) for gene delivery with low cytotoxicity and high efficiency.


2008 ◽  
Vol 19 (3) ◽  
pp. 626-633 ◽  
Author(s):  
Mei Ou ◽  
Xu-Li Wang ◽  
Rongzuo Xu ◽  
Chien-Wen Chang ◽  
David A. Bull ◽  
...  

2020 ◽  
Vol 20 ◽  
Author(s):  
L. Hajba ◽  
A. Guttman

: Adeno-associated virus (AAV) is one of the most promising viral gene delivery vectors with long-term gene expression and disease correction featuring high efficiency and excellent safety in human clinical trials. During the production of AAV vectors,there are several quality control (QC)parameters that should be rigorously monitored to comply with clini-cal safety and efficacy. This review gives a short summary of the most frequently used AVV production and purification methods,focusing on the analytical techniques applied to determine the full/empty capsid ratio and the integrity of the encapsidated therapeutic DNA of the products.


2002 ◽  
Vol 4 (2) ◽  
pp. 161-169 ◽  
Author(s):  
Elisabetta Ravot ◽  
Giuditta Comolli ◽  
Franco Lori ◽  
Julianna Lisziewicz

2001 ◽  
Vol 37 (7) ◽  
pp. 1975-1980 ◽  
Author(s):  
Philippe G Amabile ◽  
Jacob M Waugh ◽  
Thomas N Lewis ◽  
Christopher J Elkins ◽  
Wolfgang Janas ◽  
...  

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Keerat Kaur ◽  
Asharee Mahmoud ◽  
Hanna Girard ◽  
Ann Anu Kurian ◽  
Magdalena Zak ◽  
...  

Introduction: Despite various clinical modalities, ischemic heart disease remains among the leading causes of mortality and morbidity worldwide. The elemental problem is the immense loss of cardiomyocytes (CMs) post-myocardial infarction (MI). Reprogramming non- cardiomyocytes (non-CMs) into cardiomyocyte (CM)-like cells in vivo is a promising strategy for cardiac regeneration: however, the traditional viral delivery method hampered its application into clinical settings due to low and erratic transduction efficiency. Methods: We used a modified mRNA (modRNA) gene delivery platform to deliver different stoichiometry of cardiac-reprogramming genes (Gata4, Mef2c, Tbx5 and Hand2) together with reprogramming helper genes (Dominant Negative (DN)-TGFβ, DN- Wnt8a and Acid ceramidase (AC)), named 7G, to induce direct cardiac reprogramming post myocardial infarction (MI). Results: Here, we identified 7G modRNA cocktail as an important regulator ofthe cardiac reprogramming. Cardiac transfection with 7G modRNA doubled cardiac reprogramming efficiency (57%) in comparison to Gata4, Mef2C and Tbx5 (GMT) alone (28%) in vitro . By inducing MI in our lineage tracing model, we showed that one-time delivery of the 7G-modRNA cocktail reprogrammed ~25% of the non-CMs in the scar area to CM- like cells. Furthermore, 7G modRNA treated mice showed significantly improved cardiac function, longer survival, reduced scar size and greater capillary density than control mice 28 days post-MI. We attributed the improvement in heart function post modRNA delivery of 7G or 7G with increased Hand2 ratio (7G-GMT Hx2) to significant upregulation of 15 key angiogenic factors without any signs of angioma or edema. Conclusions: 7G or 7G GMT HX2 modRNA cocktails boosts de novo CM-like cells and promotes cardiovascular regeneration post-MI. Thus, we highlight that this gene delivery approach not only has high efficiency but also high margin of safety for translation to clinics.


Sign in / Sign up

Export Citation Format

Share Document